Paper Details

  1. Home
  2. Paper Details

Decitabine for acute myeloid leukemia.

Author: MarksPeter W

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This review discusses the current status of decitabine, a DNA methyltransferase inhibitor used in treating acute myeloid leukemia. Decitabine's efficacy and safety profile have led to its increasing use in older individuals and those ineligible for more intensive therapies. Further research aims to optimize its use and identify effective combinations with other drugs.
Paper Details　
Original Abstract of the Article :
Decitabine (Dacogen(®), Eisai Inc., NJ, USA) is a nucleoside analogue DNA methyltransferase inhibitor first synthesized and documented to have antileukemic efficacy over 40 years ago. Over the years, the dosing of decitabine has been refined, such that for acute myeloid leukemia, a 5-day schedule of...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1586/era.11.207

データ提供：米国国立医学図書館（NLM）

Decitabine: A Promising Treatment for Acute Myeloid Leukemia

This research, like a steadfast camel navigating the desert of cancer treatments, delves into the use of decitabine for acute myeloid leukemia (AML). The researchers examine the history and efficacy of this drug, exploring its potential as a therapy for older individuals and those who are not candidates for more intensive treatments. The study highlights decitabine's ability to inhibit DNA methyltransferase, a key enzyme in cancer development.

Decitabine: A Hope for Older Individuals with AML

This study, like a fresh oasis in the desert, provides hope for older individuals with AML. It underscores the potential of decitabine as a single-agent therapy, showing promising results in terms of antileukemic efficacy and relatively modest nonhematologic toxicity.

Making Informed Decisions About AML Treatment

The research highlights the importance of considering personalized treatment options for AML, factoring in age, overall health, and individual patient characteristics. It's vital to discuss treatment options with your doctor and make informed decisions based on your specific needs and goals.

Dr.Camel's Conclusion

This study offers a promising glimpse into the potential of decitabine as a treatment option for AML. While further research is needed to optimize its use, it provides a ray of hope for older individuals and those who may not be suitable for more intensive therapies.

Date :
  1. Date Completed 2012-07-17
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

22369322

DOI: Digital Object Identifier

10.1586/era.11.207

Related Literature

Article Analysis
・Effects of decitabine injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.